Vaccination against tick-borne encephalitis (TBE) after autologous and allogeneic stem cell transplantation
| Autor: | Bénédicte Piauger, Malin Veje, Sigrun Einarsdottir, Tomas Bergström, Mikael Lisak, Malin Nicklasson, Anette Roth, Mats Brune, Berit Johansson, Per Ljungman, Vanda Friman, Bjorn Andreasson, Marie Studahl, Mikael Olsson |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment 030231 tropical medicine Antibodies Viral Transplantation Autologous Gastroenterology Encephalitis Viruses Tick-Borne 03 medical and health sciences 0302 clinical medicine Autologous stem-cell transplantation Internal medicine medicine Humans 030212 general & internal medicine General Veterinary General Immunology and Microbiology biology business.industry Vaccination Hematopoietic Stem Cell Transplantation Public Health Environmental and Occupational Health Tick-borne encephalitis Viral Vaccines Immunosuppression Middle Aged medicine.disease Lymphoma Transplantation Infectious Diseases biology.protein Molecular Medicine Antibody Stem cell business Encephalitis Tick-Borne |
| Zdroj: | Vaccine. 39:1035-1038 |
| ISSN: | 0264-410X |
| DOI: | 10.1016/j.vaccine.2020.12.073 |
| Popis: | Introduction Our aim was to assess response and side effects of 4 doses of TBE vaccine to patients (pts) after allo- and autologous stem cell transplantation (SCT). PATIENTS: Included were 104 pts with leukaemia, myeloma and lymphoma, median age 61 yrs. METHODS: Vaccine (FSME-Immun®) was given at 9, 10, 12, and 21 months post-transplant. Serum samples were obtained before and after vaccinations. Healthy controls (n = 27) received 3 vaccinations. Assessments of TBE specific IgG antibodies were performed by Enzygnost anti-TBE ELISA test (Siemens, Sweden). Results Antibody levels (>12 U/mL; “seropositivity”) were seen in 77% and 80% of pts after allo- and autoSCT; IgG levels; 89 vs 94 U/mL. Ongoing chronic GvHD and immunosuppression (n = 29) was associated with sero-negativity in the last sample (p = 0.007). All controls (n = 27) developed protective antibody levels. Conclusions TBE vaccination was safe, and 4 doses starting 9 months post-SCT, induced seropositivity in a vast majority of pts. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect